Data Sheet (Cat.No.T0890)

TargetMol

Mefenamic acid

Chemical Properties



CAS No. : 61-68-7

Formula: C15H15NO2

Molecular Weight: 241.29

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Mefenamic acid (CN-35355) is a non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.
Targets(IC50)	COX

Solubility Information

Solubility	Ethanol: < 1 mg/mL (insoluble or slightly soluble), DMSO: 250 mg/mL (1036.1 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+90% Saline: < 10 mg/mL (41.44 mM),Lower concentrations may be soluble, but exact solubility limit is unknown. 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 10 mg/mL (41.44 mM),Suspension. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	4.1444 mL	20.722 mL	41.4439 mL
5 mM	0.8289 mL	4.1444 mL	8.2888 mL
10 mM	0.4144 mL	2.0722 mL	4.1444 mL
50 mM	0.0829 mL	0.4144 mL	0.8289 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Bhat AS, et al. Eur J Pharmacol. 2007 Feb 5; 556(1-3):190-9.
Jiang H, He H, Chen Y, et al. Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. Journal of Experimental Medicine. 2017, 214(11): 3219-3238.
Jiang H, He H, Chen Y, et al. Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders [J]. Journal of Experimental Medicine. 2017, 214(11): 3219-3238.